Derek O'Hagan

GSK Vaccine Research

I am currently a Senior Advisor in Technical R&D in GSK Vaccines, a role I undertook in mid-2018. Prior to this I was the Global Head of Discovery Support and New Technology, with Discovery facing staff at the three R&D centers for GSK vaccines, in Rockville, MD, Rixensart, Belgium and Siena, Italy. Our role was to support the Discovery Teams to ensure smooth transition of Projects and Platforms into Development, through ensuring all necessary data was in place, following QbD principles to ensure an appropriate level of product/process understanding to justify clinical evaluation. Until 2015, I was the Global Head of Vaccine Chemistry and Formulation Research for Novartis Vaccines, based in Cambridge, MA until acquisition by GSK. I managed research teams (~50 total staff) in Cambridge and Siena, Italy. I originally qualified as a pharmacist in the UK, and I have worked on vaccine delivery/formulation in the industry since 1993. I was formerly a Lecturer in Drug Delivery at the Department of Pharmaceutical Sciences, University of Nottingham, UK, and received research funding from the World Health Organization, The Wellcome Trust and the Medical Research Council. I was recruited into the US in 1993, to progress basic research into clinical evaluation. I subsequently worked on several novel vaccine delivery concepts that were evaluated in the clinic, including adjuvants for recombinant proteins, nucleic acid vaccines (RNA and DNA), needle free vaccines and adeno vectors. In the mid 1990’s, I worked on the emulsion adjuvant MF59, which is now included in licensed flu vaccines in more than 40 countries, including the US. I have also worked on several additional vaccines which are in various stages of clinical development, or have already been licensed. I have co-authored >140 original research publications, >50 reviews and I am a named inventor on >60 filed patents. I was awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain in 1997, and the Young Investigator Research Achievement Award of the Controlled Release Society in 1999. I was also named as the ‘most inventive scientist’ in Chiron in 2004 and was the lead author on the most cited paper in ‘Vaccine’ 2008-10. I served on the Board of Scientific Advisors for the Controlled Release Society and I am a Fellow of the American Association of Pharmaceutical Scientists.

Sessions